We narrowed to 5,836 results for: dre

#121539-AAV5

Ready-to-use AAV5 particles produced from pOTTC1596 - pAAV SYN1 HA-hM3D(Gq) (#121539). In addition to the viral particles, you will also receive purified pOTTC1596 - pAAV SYN1 HA-hM3D(Gq) plasmid DNA. Synapsin-driven, HA-tagged hM3D(Gq) for neuronal activation. These AAV preparations are suitable purity for injection into animals.

Christopher Richie

Galvan et al Eur J Neurosci. 2019 May 7. doi: 10.1111

Feb. 21, 2019

Academic Institutions and Nonprofits only

#121539-AAVrg

Ready-to-use AAV Retrograde particles produced from pOTTC1596 - pAAV SYN1 HA-hM3D(Gq) (#121539). In addition to the viral particles, you will also receive purified pOTTC1596 - pAAV SYN1 HA-hM3D(Gq) plasmid DNA. Synapsin-driven, HA-tagged hM3D(Gq) for neuronal activation. These AAV preparations are suitable purity for injection into animals.

Christopher Richie

Galvan et al Eur J Neurosci. 2019 May 7. doi: 10.1111

Aug. 7, 2025

Academic Institutions and Nonprofits only

#121539-AAV2

Ready-to-use AAV2 particles produced from pOTTC1596 - pAAV SYN1 HA-hM3D(Gq) (#121539). In addition to the viral particles, you will also receive purified pOTTC1596 - pAAV SYN1 HA-hM3D(Gq) plasmid DNA. Synapsin-driven, HA-tagged hM3D(Gq) for neuronal activation. These AAV preparations are suitable purity for injection into animals.

Christopher Richie

Galvan et al Eur J Neurosci. 2019 May 7. doi: 10.1111

April 3, 2023

Academic Institutions and Nonprofits only

#121538-AAV2

Ready-to-use AAV2 particles produced from pOTTC1484 - pAAV SYN1 HA-hM4D(Gi) (#121538). In addition to the viral particles, you will also receive purified pOTTC1484 - pAAV SYN1 HA-hM4D(Gi) plasmid DNA. Synapsin-driven, HA-tagged hM4D(Gi) for neuronal inhibition. These AAV preparations are suitable purity for injection into animals.

Christopher Richie

Galvan et al Eur J Neurosci. 2019 May 7. doi: 10.1111

Sept. 25, 2019

Academic Institutions and Nonprofits only

#69571-AAV1

Ready-to-use AAV1 particles produced from pAAV-EF1a-C-CreintG (#69571). In addition to the viral particles, you will also receive purified pAAV-EF1a-C-CreintG plasmid DNA. EF1a-driven expression of optimized C-terminal component of Cre recombinase dependent on GFP (Cre-DOG OPT); to be coinjected with pAAV-EF1a-N-CretrcintG (Addgene catalog# 69570) and GFP (or for use with transgenic GFP animals). These AAV preparations are suitable purity for injection into animals.

Connie Cepko

Tang et al Nat Neurosci. 2015 Sep;18(9):1334-41. do

Feb. 19, 2020

Academic Institutions and Nonprofits only

#69570-AAV1

Ready-to-use AAV1 particles produced from pAAV-EF1a-N-CretrcintG (#69570). In addition to the viral particles, you will also receive purified pAAV-EF1a-N-CretrcintG plasmid DNA. EF1a-driven expression of optimized N-terminal component of Cre recombinase dependent on GFP (Cre-DOG OPT); to be coinjected with pAAV-EF1a-C-CreintG (Addgene catalog# 69571) and GFP (or for use with transgenic GFP animals). These AAV preparations are suitable purity for injection into animals.

Connie Cepko

Tang et al Nat Neurosci. 2015 Sep;18(9):1334-41. do

Feb. 19, 2020

Academic Institutions and Nonprofits only

#154868-AAV8

Ready-to-use AAV8 particles produced from pAAV-hSyn-fDIO-hM3D(Gq)-mCherry-WPREpA (#154868). In addition to the viral particles, you will also receive purified pAAV-hSyn-fDIO-hM3D(Gq)-mCherry-WPREpA plasmid DNA. Syn-driven, Flp-dependent hM3D(Gq) receptor with an mCherry reporter for CNO-induced neuronal activation. These AAV preparations are suitable purity for injection into animals.

Ulrik Gether

Aug. 19, 2022

Academic Institutions and Nonprofits only

#154868-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-hSyn-fDIO-hM3D(Gq)-mCherry-WPREpA (#154868). In addition to the viral particles, you will also receive purified pAAV-hSyn-fDIO-hM3D(Gq)-mCherry-WPREpA plasmid DNA. Syn-driven, Flp-dependent hM3D(Gq) receptor with an mCherry reporter for CNO-induced neuronal activation. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Ulrik Gether

Oct. 8, 2020

Academic Institutions and Nonprofits only

#228902-AAV8

Ready-to-use AAV8 particles produced from pAAV-CAG-DIO-HA-HCARD-P2A-mCitrine (#228902). In addition to the viral particles, you will also receive purified pAAV-CAG-DIO-HA-HCARD-P2A-mCitrine plasmid DNA. CAG-driven, Cre dependent expression of a peripherally restricted DREADD. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

Kang et al Cell. 2024 Dec 26;187(26):7433-7449.e20.

Oct. 8, 2025

Academic Institutions and Nonprofits only

#135635-AAV9

Ready-to-use AAV9 particles produced from pAAV-S5E2-Gq-P2A-dTomato (#135635). In addition to the viral particles, you will also receive purified pAAV-S5E2-Gq-P2A-dTomato plasmid DNA. Expression of Gq-DREADD and dTomato (physically separate) under the control of the E2 regulatory element. These AAV preparations are suitable purity for injection into animals.

Jordane Dimidschstein

Vormstein-Schneider et al Nat Neurosci. 2020 Dec;23(12):1629-1636.

Aug. 27, 2021

Academic Institutions and Nonprofits only

#135635-AAV1

Ready-to-use AAV1 particles produced from pAAV-S5E2-Gq-P2A-dTomato (#135635). In addition to the viral particles, you will also receive purified pAAV-S5E2-Gq-P2A-dTomato plasmid DNA. Expression of Gq-DREADD and dTomato (physically separate) under the control of the E2 regulatory element. These AAV preparations are suitable purity for injection into animals.

Jordane Dimidschstein

Vormstein-Schneider et al Nat Neurosci. 2020 Dec;23(12):1629-1636.

Nov. 29, 2021

Academic Institutions and Nonprofits only

#135635-PHPeB

Ready-to-use AAV PHP.eB particles produced from pAAV-S5E2-Gq-P2A-dTomato (#135635). In addition to the viral particles, you will also receive purified pAAV-S5E2-Gq-P2A-dTomato plasmid DNA. Expression of Gq-DREADD and dTomato (physically separate) under the control of the E2 regulatory element. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Jordane Dimidschstein

Vormstein-Schneider et al Nat Neurosci. 2020 Dec;23(12):1629-1636.

Aug. 27, 2021

Academic Institutions and Nonprofits only